Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors
Status:
RECRUITING
Trial end date:
2030-09-01
Target enrollment:
Participant gender:
Summary
To study possible biomarkers that may be related to how SAR444881 works (either alone or when combined with cemiplimab) in participants with solid tumors.